Experienced in Bladder Cancer

Dr. Sunil G. Gandhi

Oncology | Hematology
Florida Cancer Specialists And Research Institute, LLC
521 N Lecanto Hwy, Florida Cancer Specialists, 
Lecanto, FL 
Accepting New Patients
Offers Telehealth
43 Years of Experience
Experienced in Bladder Cancer
Florida Cancer Specialists And Research Institute, LLC
521 N Lecanto Hwy, Florida Cancer Specialists, 
Lecanto, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sunil Gandhi is an Oncologist and a Hematologist in Lecanto, Florida. Dr. Gandhi has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Anal Cancer, Anemia, Familial Colorectal Cancer, Lung Cancer, and Bone Marrow Aspiration. Dr. Gandhi is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Bladder Cancer.

Graduate Year
1982
Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Hca Florida Citrus Hospital
Tampa General Hospital Crystal River
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
521 N Lecanto Hwy, Florida Cancer Specialists, Lecanto, FL 34461

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

6 Total Publications

MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Journal: Radiology
Published: September 03, 2024
Similar Doctors
Distinguished in Bladder Cancer
Dr. Jingsong L. Zhang
Oncology
Distinguished in Bladder Cancer
Dr. Jingsong L. Zhang
Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (55.8 miles away)
888-860-2778
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Jingsong Zhang is an Oncologist in Tampa, Florida. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), and Liver Embolization. Dr. Zhang is currently accepting new patients.

Advanced in Bladder Cancer
Dr. Ketan Doshi
Hematology | Oncology
Advanced in Bladder Cancer
Dr. Ketan Doshi
Hematology | Oncology

Ocala Oncology Center Pl

13940 Us Hwy 441 N, Suite 203, 
Lady Lake, FL 
 (35.1 miles away)
352-259-8940
Languages Spoken:
English
See accepted insurances

Ketan Doshi is a Hematologist and an Oncologist in Lady Lake, Florida. Dr. Doshi is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Anemia, Chronic Familial Neutropenia, Agranulocytosis, and Severe Congenital Neutropenia.

Advanced in Bladder Cancer
Dr. Andrew M. Weber
Hematology | Hematology Oncology | Oncology
Advanced in Bladder Cancer
Dr. Andrew M. Weber
Hematology | Hematology Oncology | Oncology

Ocala Oncology Center Pl

3130 Sw 32nd Ave, 
Ocala, FL 
 (27.4 miles away)
352-732-4032
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Weber is a Hematologist and a Hematologist Oncology provider in Ocala, Florida. Dr. Weber is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Febrile Neutropenia. Dr. Weber is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gandhi's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 86 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile